The emerging concept of "individualized cholesterol-lowering therapy" : A change in paradigm

Copyright © 2019 Elsevier Inc. All rights reserved.

Bibliographic Details
Published in:Pharmacology & therapeutics, Vol. 199 (2019), p. 111-116
Main Author: Lütjohann, Dieter
Other Involved Persons: Stellaard, Frans ; Mulder, Monique T ; Sijbrands, Eric J G ; Weingärtner, Oliver
Format: electronic Article
Language:English
ISSN:1879-016X
Item Description:Date Revised 15.06.2019
published: Print-Electronic
Citation Status In-Data-Review
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1016/j.pharmthera.2019.03.004
Subjects:
QR Code: Show QR Code
LEADER 03101nma a2200589 c 4500
001 NLM295544554
003 DE-601
005 20190626000742.0
007 cr uuu---uuuuu
008 190318s2019 000 0 eng d
024 7 |a 10.1016/j.pharmthera.2019.03.004  |2 doi 
028 5 2 |a pubmed19n1240.xml 
035 |a S0163-7258(19)30043-9 
035 |a (DE-599)NLM30877023 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Lütjohann, Dieter 
245 1 4 |a The emerging concept of "individualized cholesterol-lowering therapy"  |h Elektronische Ressource  |b A change in paradigm 
300 |a Online-Ressource 
500 |a Date Revised 15.06.2019 
500 |a published: Print-Electronic 
500 |a Citation Status In-Data-Review 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2019 Elsevier Inc. All rights reserved. 
520 |a High LDL-cholesterol concentrations constitute a risk for atherosclerotic cardiovascular disease. By consensus, cholesterol-lowering therapy is initiated with a statin that reduces endogenous cholesterol synthesis, upregulates hepatic LDL receptor activity, increases LDL clearance and lowers LDL-cholesterol concentrations in the bloodstream. The efficacy of statin treatment is dose dependent and achieves a risk reduction of up to 50%. However, a substantial body of evidence suggests that a quarter of statin-treated patients do not respond adequately as a result of low endogenous cholesterol synthesis. In humans fractional cholesterol absorption varies from 20% to 80%. High cholesterol absorbers, which are characterized by a low-to-normal cholesterol synthesis, exhibit poor responsiveness to statin treatment. On the other hand, the cholesterol absorption inhibitor ezetimibe effectively reduces serum cholesterol levels in these patients. On this background, we suggest to "get personal" and individualize cholesterol-lowering therapies, according to the individual's status of cholesterol synthesis and absorption 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
655 7 |a Acute coronary syndrome  |2 gnd 
655 7 |a Cholesterol balance  |2 gnd 
655 7 |a Cholesterol synthesis  |2 gnd 
655 7 |a Coronary artery disease  |2 gnd 
655 7 |a Lipid metabolism  |2 gnd 
655 7 |a Sterol absorption  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Acute coronary syndrome 
689 1 1 |a Cholesterol balance 
689 1 2 |a Cholesterol synthesis 
689 1 3 |a Coronary artery disease 
689 1 4 |a Lipid metabolism 
689 1 5 |a Sterol absorption 
689 1 |5 DE-601 
700 1 |a Stellaard, Frans 
700 1 |a Mulder, Monique T 
700 1 |a Sijbrands, Eric J G 
700 1 |a Weingärtner, Oliver 
773 0 8 |i in  |t Pharmacology & therapeutics  |g Vol. 199 (2019), p. 111-116  |q 199<111-116  |w (DE-601)NLM000442402  |x 1879-016X 
856 4 1 |u http://dx.doi.org/10.1016/j.pharmthera.2019.03.004  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 199  |j 2019  |c 07  |h 111-116